Trial Profile
A phase I, multiple ascending dose trial of recombinant human erythropoietin (rhEPO-Fc)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 May 2017
Price :
$35
*
At a glance
- Drugs Recombinant erythropoietin (Primary)
- Indications Anaemia
- Focus Adverse reactions
- Sponsors Uni-Bio Science Group
- 16 May 2017 New trial record